Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies

References

• Allen KD, Golightly YM. Epidemiology of osteoarthritis: state of the evidence. Curr Opin Rheumatol 2015;27:276-83
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Reginster JY. The economic weight of osteoarthritis in Europe. Mediographia 2013;35:197-201. http://www.medicographia.com/wp-content/pdf/Medicographia115.pdf. Accessed April 11, 2016
   Google Scholar
• Hochman JR, French MR, Bermingham SL, et al. The nerve of osteoarthritis pain. Arthritis Care Res 2010;62:1019-23
   PubMed Web of Science ®Google Scholar
• Hochman JR, Gagliese L, Davis AM, et al. Neuropathic pain symptoms in a community knee OA cohort. Osteoarthritis Cartilage 2011;19:647-54
   PubMed Web of Science ®Google Scholar
• Ohtori S, Orita S, Yamashita M, et al. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. Yonsei Med J 2012;53:801-5
   PubMed Web of Science ®Google Scholar
• Hochman JR, Davis AM, Elkayam J, et al. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. Osteoarthritis Cartilage 2013;21:1236-42
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573-81
   PubMed Web of Science ®Google Scholar
• Lluch E, Torres R, Nijs J, et al. Evidence for central sensitization in patients with osteoarthritis pain: a systematic literature review. Eur J Pain 2014;18:1367-75
   PubMed Web of Science ®Google Scholar
• Lluch Girbés E, Nijs J, Torres-Cueco R, et al. Pain treatment for patients with osteoarthritis and central sensitization. Phys Ther 2013;93:842-51
   PubMed Web of Science ®Google Scholar
• Nijs J, Malfliet A, Ickmans K, et al. Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update. Expert Opin Pharmacother 2014;15:1671-83
   PubMed Web of Science ®Google Scholar
• Ossipov M, Morimura K, Porreca F. Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care 2014;8:143-51
   PubMed Web of Science ®Google Scholar
• Akinci A, Al Shaker M, Chang MH, et al. Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitization component. Int J Clin Pract 2016;70:31-44
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014;28:319-29
   PubMed Web of Science ®Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain—a review of clinical trials and five years of routine clinical practice data. Pain Practice 2016; Sept 9 Epub ahead of print. DOI:10.1111/papr.12515
   Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pin related to osteoarthritis of the knee. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Practice 2010;10:416-27
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Müller M, Kujawa J, et al. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res 2012;5:121-38
   PubMedGoogle Scholar
• Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig 2013;33:607-19
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther 2015;37:2420-38
   PubMed Web of Science ®Google Scholar
• Serrie A, Lange B, Steup A. Tapentadol prolonged released for moderate to severe chronic osteoarthritis knee pain—a double-blind, randomized, placebo- and oxycodone-controlled study. Curr Med Res Opin. doi: 10.1080/03007995.2017.1335189
   Web of Science ®Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for pschopharmacology (DHEW Publication no. ADM 76-338). Washington (DC): US Government Printing Office; 1976
   Google Scholar
• The EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Sánchez del Águila MJ, Schenk M, Kern K-U, et al. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 2015;37:94-113
   PubMed Web of Science ®Google Scholar
• Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA project. J Clin Epidemiol 1998;51:1171-8
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-804
   PubMed Web of Science ®Google Scholar
• Etropolski M, Kuperwasser B, Flügel M, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther 2014;31:604-20
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl. Drugs Future 2006;31:1053-61
   Web of Science ®Google Scholar